The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

Venetoclax is a promising agent in the treatment of acute myeloid leukemia (AML), though its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim upregulation, and DNA damage have been identified as potential ways to enhance venetoclax activity. In this study, we comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinyu, Su, Yongwei, Hege, Katie, Madlambayan, Gerard, Edwards, Holly, Knight, Tristan, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Yang, Jay, Miller, Regan, Wang, Guan, Zhao, Lijing, Wang, Yue, Lin, Hai, Taub, Jeffrey W., Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094102/
https://www.ncbi.nlm.nih.gov/pubmed/32165486
http://dx.doi.org/10.3324/haematol.2019.233445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094102/
https://www.ncbi.nlm.nih.gov/pubmed/32165486
http://dx.doi.org/10.3324/haematol.2019.233445

Ejemplares similares